Anna Nordvig, MD

Anna Nordvig, MD Specialties: Neurology

Anna Nordvig, MD
Specialties: Neurology
phone icon
"

Address

428 East 72nd Street
Suite 500
New York, NY 10021
US

insurance iconinsurance icon
Insurances Accepted

Please contact the doctor's office to verify that your insurance is accepted.

  • Aetna - NYP
  • Aetna - Weill Cornell
  • Empire Blue Cross/Blue Shield
  • GHI
  • Health Insurance Plan of NY (HIP)
  • Oxford Health Plans
  • United Healthcare

about iconabout icon
About Anna Nordvig, MD

Anna S. Nordvig, M.D. specializes in cognitive disorders of the brain. She is a board-certified neurologist at the NY Presbyterian/ Weill Cornell Memory Disorders Program. She completed a fellowship in Behavioral Neurology and Neuropsychiatry in the Division of Aging and Dementia at the Neurological Institute at Columbia University Medical Center. There she also completed her medicine internship and neurology residency. Dr. Nordvig decided to study medicine after a career in business. She felt a calling to care for patients, and to investigate the mysteries of the aging brain through research inspired by her patient's questions.


In addition to caring for dementia patients, Dr. Nordvig is building an outpatient clinical and translational research program in post-COVID encephalopathy ("brain fog"). Some of her findings are published in *Neurology: Clinical Practice, Nature Medicine, npj Nature Parkinson's Disease,*and Acta Neuropathologica. She was an invited presenter at the Cold Spring Harbor Laboratory Conference on Neurodegeneration, the BRAIN UK conference, and a Continuing Medical Education course. Dr. Nordvig has received funding through a T32 NIH grant as well as a National Institute on Aging Alzheimer's Disease Research Center Career Development Award.


Dr. Nordvig is working to understand post-COVID-19 encephalopathy through neuropsychological phenotyping, biofluidics, and imaging techniques. Her goal is to understand the implications of post-COVID-19 encephalopathy (as a model of acute systemic inflammation) for neurodegeneration – it a risk factor, an early biomarker, and/or a trigger?


Expertise

  • Alzheimer's Disease

  • Memory Disorder